Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06852365 · ClinicalTrials.gov registry record · Phase 2

Combined Oral Contraceptive Pill and Resistance Starch

A Phase 2 study of Metabolic Syndrome and Polycystic Ovary Syndrome, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
1
Study location

NCT06852365 is a Phase 2 study of Metabolic Syndrome and Polycystic Ovary Syndrome that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06852365, a Phase 2 study of Metabolic Syndrome and Polycystic Ovary Syndrome, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.

Interventions

  • DIETARY_SUPPLEMENT wheat dextrin
  • DRUG Oral Contraceptives, Low-Dose
  • DIETARY_SUPPLEMENT Maltodextrin

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-06-10
Est. Completion 2028-04
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT06852365

The ClinicalTrials.gov registry entry for NCT06852365 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 3 interventions - of which wheat dextrin is the first listed.

NCT06852365 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06852365 about?

NCT06852365 is a clinical study titled "Combined Oral Contraceptive Pill and Resistance Starch". This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.

What is the current status of trial NCT06852365?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-10. Estimated completion is 2028-04.

What conditions does trial NCT06852365 study?

This clinical trial studies the following conditions: Metabolic Syndrome, Polycystic Ovary Syndrome.

What interventions are being tested in trial NCT06852365?

The interventions under investigation include: wheat dextrin (DIETARY_SUPPLEMENT), Oral Contraceptives, Low-Dose (DRUG), Maltodextrin (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06852365?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06852365 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.